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Radiation oncologists have observed variation in normal tissue responses between patients
in many instances with no apparent explanation.The association of clinical tissue radiosen-
sitivity with specific genetic repair defects (Wegner’s syndrome, Ataxia telangiectasia,
Bloom’s syndrome, and Fanconi anemia) has been well established, but there are unex-
plained differences between patients in the general population with respect to the intensity
and rapidity of appearance of normal tissue toxicity including radiation dermatitis, oral cav-
ity mucositis, esophagitis, as well as differences in response of normal tissues to standard
analgesic or other palliative measures. Strategies for the use of clinical radioprotectors
have included modalities designed to either prevent and/or palliate the consequences of
radiosensitivity. Most prominently, modification of total dose, fraction size, or total time
of treatment delivery has been necessary in many patients, but such modifications may
reduce the likelihood of local control and/or radiocurability. As a model system in which to
study potential radioprotection by mitochondrial-targeted antioxidant small molecules, we
have studied cell lines and tissues from Fanconi anemia (Fancd2−/−) mice of two back-
ground strains (C57BL/6NHsd and FVB/N). Both were shown to be radiosensitive with
respect to clonogenic survival curves of bone marrow stromal cells in culture and severity
of oral cavity mucositis during single fraction or fractionated radiotherapy. Oral administra-
tion of the antioxidant GS-nitroxide, JP4-039, provided significant radioprotection, and also
ameliorated distant bone marrow suppression (abscopal effect of irradiation) in Fancd2−/−
mice. These data suggest that radiation protection by targeting the mitochondria may
be of therapeutic benefit even in the setting of defects in the DNA repair process for
irradiation-induced DNA double strand breaks.
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INTRODUCTION
The relative susceptibility of individual patients to acute and
chronic side effects of therapeutic ionizing irradiation has been the
subject of intense controversy (1). Radiation oncologists expect
a greater degree of acute side effects as target volumes, radia-
tion fraction size, and total dose increase, and overall treatment
time is decreased (1). Concern for the parameters of acute tissue
toxicity has led to innovative and valuable modifications of radio-
therapy technology including intensity modulated radiotherapy,
stereotactic radiosurgery, image-guided radiotherapy, and respira-
tory gating. These modalities have facilitated a decrease in overall
tissue dose (integral dose) and are designed to reduce acute radio-
therapy side effects. Most prominently, the use of brachytherapy
techniques in which ionizing irradiation sources are implanted
permanently or transiently into tissues greatly reduces total tar-
get dose. These principals have been applied to clinical radiation
therapy for over 100 years (1).
Despite uniform approaches toward reducing normal tissue
toxicity, there remain continual reports of variation between
patients with respect to the likelihood of developing rapid normal
tissue damage effects, symptomatology, and potential requirement
for radiotherapy treatment breaks, reduced total dose, or reduced
fraction size. The mechanism of the radiosensitivity of tissues
in specific patients is not always available. Specific DNA repair
defects have been associated with radiosensitivity. These include
the genetic defects in ataxia telangiectasia, Bloom’s syndrome,
Wegner’s syndrome, and Fanconi anemia (1–4). However, even
within these rare disease categories, there remains heterogeneity
with respect to expression of the phenotypic response of clini-
cal radiosensitivity. In particular, Fanconi anemia is diagnosed by
specific clinical attributes of short stature, abnormality of thumb
morphology, café au lait spots, and other observable phenotypic
changes, but these are not always present in FA patients (5–7).
FA is then confirmed by sensitivity of cells to DNA cross-linking
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agents such as mitomycin C (6, 7). Given the complexity of the
FA pathway, involving 15 or more proteins, the repair mechanism
in this clinical syndrome has been termed one of a “defect in the
scaffolding” of DNA repair process (6, 7). FA proteins serve as a
base for the complex interaction of proteins in DNA double strand
break repair. While two patients may be diagnosed with FA and
in fact have defects at the level of the same protein (for example,
FANC-A), one may be radiosensitive and the other may not (5).
This observation is particularly important, because of the presence
in FA patients of a high likelihood development of epithelial can-
cers, including head and neck cancer. There are many reports of FA
patients who suffer significant morbidity of clinical radiotherapy,
including inability to tolerate standard clinical fractionation for a
5.5 weeks course of post-operative radiotherapy for head and neck
cancer (5). Given the same genotypic complement in FA patients
with defects in the same protein of the same pathway, radiation
oncologists have been cautious in treating FA patients, knowing
that some will experience significant normal tissue toxicity. Fur-
thermore, the use of radiotherapy in treatment of FA patients has
been discouraged by many investigators in the field because of the
likelihood of significant side effects (5).
MATERIALS AND METHODS
MICE AND ANIMAL CARE
Fanconi anemia (Fancd2−/−) mice were bred from the mating of
Fancd2+/− heterozygote pairs and were derived from either the
C57BL/6 background (2) or the FVB/N background (3) strains.
Mice were housed four per cage according to Institutional IACUC
guidelines and fed standard Purina® chow and deionized water.
Animals for irradiation studies were uniformly 6–8 weeks of age
and both males and females were studied.
ANIMAL IRRADIATION
Total body irradiation was carried out using a cesium gamma cell
irradiator at 70 cGy (8). Head and neck irradiation was carried out
using a Varian Clinac 6 mV linear accelerator radiation beam and
using a technique whereby thoracic cavity and abdomen as well as
all four limbs were shielded such that only the head and neck were
irradiated. All irradiation doses were calibrated using thermolu-
minescent dosimeters and dose rate was uniformly 200 cGy/min
(9, 10).
IN VITRO RADIATION STUDIES
Bone marrow stromal cell lines from several mouse strains
were derived from the adherent layer of long-term bone mar-
row cultures (11). Briefly, long-term bone marrow cultures were
established from Fancd2−/−, Fancd2+/−, and Fancd2+/+ mice
(C57BL/6J mouse strain). Non-adherent cells were removed
weekly and assayed for total cells produced, as well as those cells
capable of producing colonies in semi-solid medium in secondary
culture. Colonies were scored at day 7 and day 14. The results
of these studies showed significant decrease in the capacity of cul-
tures to produce hematopoietic cells over 22 weeks (Permanent cell
lines were established from the adherent layer of these long-term
bone marrow cultures and produced cell lines that are adherent in
culture and fibroblastic. These are also called mesenchymal stem
cells.). Non-adherent cells from the 4-week harvest of long-term
marrow cultures were carried in medium supplemented with IL-3
and clonal cell lines established. These are termed hematopoi-
etic cells and are IL-3-dependent multilineage colony forming
cells capable of forming neutrophils, macrophages, erythroid cells,
megakaryocytes, and monocytes. Briefly, the adherent cell layer
from 4-week-old continuous marrow cultures was trypsinized
and cells were passaged weekly in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum and antibi-
otics according to published methods. After 10 weeks of passage,
cell lines were cloned by limiting dilution technique in 96 well
plates and using Poisson statistics. Single cell-derived clonal lines
were passaged weekly according to published methods.
Interleukin-3 (IL-3)-dependent hematopoietic progenitor cell
lines were derived from the non-adherent cells of 4-week-old long-
term bone marrow cultures and were passaged in Iscove’s medium
supplemented with 10% fetal bovine serum and 10µM recombi-
nant murine IL-3 (12), according to published methods. Cells for
radiation survival curves were utilized from cultures that had been
passaged for at least 10 weeks in vitro.
Bone marrow stromal cell line irradiation survival curves were
carried out with cells irradiated to doses between 0 and 800 cGy
using a cesium gamma cell irradiator. Cells were plated in six well
tissue culture plates and colonies on the adherent layer consist-
ing of >50 cells per colony were scored at day 7. IL-3-dependent
hematopoietic progenitor cell lines were irradiated in suspension
culture to doses described above, but then plated into semi-
solid medium culture containing 0.8% methylcellulose containing
Iscove’s medium supplemented with 10µM IL-3. Non-adherent
cell-derived colonies in agar secondary culture of size greater than
50 cells were scored at day 7 (11, 12).
Plating densities for both adherent stromal and non-adherent,
IL-3-dependent cells were varied such that colonies counted at
day 7 were in the range of 100/dish. Statistical analysis was carried
out and p-values <0.05 were considered statistically significant.
All the radiation survival curve studies were done in triplicate and
the results calculated based on the average of three experiments
(11, 12).
ASSAYS FOR DNA DOUBLE STRAND BREAKS
DNA double strand breaks were measured by a Comet assay using
a kit method (11). Briefly, bone marrow stromal cell lines, mes-
enchymal stem cells, or IL-3-dependent hematopoietic progenitor
cell lines (hematopoietic cells) were irradiated to doses of 0 or
5 Gy, and then cells removed from suspension culture, placed on
gel to assay for the migration of DNA fragments. The migration
of DNA fragments is characterized as a Comet-“Tail,” and the long
“Tail” is indicative of small DNA fragments migrating far from the
initial cell nucleus. At least 1000 individual cells were scored for
each irradiation dose, and a mean and standard error calculated
based on the length of the Comet-“Tail.”
ASSAY FOR ANTIOXIDANT STORES WITHIN CELLS AND TISSUES
The Trolox assay was carried out to measure antioxidant
stores (11). Fancd2+/+, Fancd2+/−, and Fancd2−/− mouse stro-
mal and IL-3-dependent hematopoietic progenitor cell lines were
irradiated to doses of 0, 5, or 10 Gy. Cells were harvested at 24 h
after irradiation and snap frozen on liquid nitrogen. Cell pellets
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were then thawed and mechanically homogenized in cold phos-
phate buffered solution. Protein concentrations were standardized
by Bradford assay to 1 mg/mL of protein sample, and antioxi-
dant reductive capacity (antioxidant status) was measured using
a commercial kit (Northwest Life Science Specialties, Vancouver,
BC, Canada). This assay measures the antioxidant capacity of cells
based on the ability of cellular antioxidants to reduce Cu++ to
Cu+, which reacts with bathocuproine to form a color complex
absorbing at 480–490 nm. The antioxidant capacity was compared
to a standard curve generator using Trolox units and all data
was, therefore, expressed as millimolar or equivalents of Trolox
units (11).
HISTOPATHOLOGIC EVALUATION OF IRRADIATED TISSUES
Oral cavity irradiation damage was scored as percent ulceration in
sections of tongue tissue removed at various times after head and
neck irradiation of mice (non-anesthetized). At least five sections
per animal, and at least 20 animals per experiment were analyzed.
Over 1000 high power microscopic fields were scored for percent
ulceration, and the results presented as the percent ulceration (9,
10). The surface area of oral cavity tissue or tongue was stan-
dardized to unirradiated control as 100% intact epithelium. The
percent of the surface area on these slides that was denuded, or
replaced by ulceration or damage to the surface area, was then
calculated based on examination of the slides. All data are pre-
sented as “percent ulceration,” which was scored on at least 10
slides/sample.
ANTIOXIDANT SMALL MOLECULE THERAPY USING GS-NITROXIDE
The small molecule GS-nitroxide, JP4-039 (8, 13), and related
analogs are established radioprotectors and target mitochondria
(14,15). These drugs have been compared,and JP4-039 was used in
the present studies. JP4-039 is in the category of hemigramicidin-
targeting of the antioxidant 4-Amino-Tempol, and is used in
radiation protection and mitigation studies, because of its small
size. The mitochondrial targeting sequence is the smallest in JP4-
039 compared to multiple other GS-nitroxides in that class (8, 13).
For in vitro radiation protection and mitigation experiments, the
compound was administered at 10µM, and JP4-039 was added
either one hour before irradiation or immediately after irradia-
tion and maintained in the culture plates for 7 days up to the time
of scoring the colony assay.
For in vivo experiments, JP4-039 was suspended in a novel
emulsion (F15) containing Tween detergent, which facilitates
localization of the compound in the locally applied tissue (16).
Visualization of the small molecule to the mitochondria of
cells in culture was carried out using a fluorescent BODIPY®-
labeled modification of JP4-039 (17). For in vivo experiments,
JP4-039/F15 was administered in a 100µL volume intraorally
to non-anesthetized mice containing 4 mg/ml JP4-039. Con-
trol groups received F15 emulsion alone in the same 100µL
volume.
ANIMAL SAFETY AND IACUC REGULATIONS
For all in vivo experiments, animal suffering was minimized and
animals were sacrificed when greater than 20% body weight was
reduced or significant morbidity from irradiation was determined.
RESULTS
Fancd2−/− MICE ARE AN EXCELLENT MODEL SYSTEM FOR RADIATION
SENSITIVITY ISSUES IN HEAD AND NECK IRRADIATION
Fancd2−/−, heterozygote Fancd2+/−, and wild type controls from
the same litters (Fancd2+/+) were derived from both the C57BL/6J
and the FVB/N background. The advantage of having Fancd2−/−
mice from two different genetic background mouse strains added
robustness to the data for any experiments purporting to show
radiosensitivity of normal tissues. As shown in Table 1, summary
of data from previous publications indicates that compared to
the heterozygote and wild type Fancd2+/+ littermates, Fancd2−/−
mice of both strains were markedly radiosensitive. In particu-
lar, bone marrow stromal cells and hematopoietic progenitor cells
show distinctly different phenotypes with respect to radiation sen-
sitivity (11). Bone marrow stromal cells are radiosensitive (11),
while hematopoietic progenitor cells are radiation resistant (11).
Since intact Fancd2−/− mice display radiosensitivity in response
to total body irradiation (2), the conclusion from these studies
has been that the sensitivity of the microenvironment (mesenchy-
mal stem cells, bone marrow stromal cells) communicates to
hematopoietic cells the phenotype of radiosensitivity of the organ
of the bone marrow. Current research in Fancd2−/− mice has sug-
gested that the profound radiosensitivity of the animals to total
body irradiation is mediated through destruction of hematopoi-
etic stem cells through DNA double strand breaks (4). Recent
evidence suggests that aldehydes intrinsically produced by all cells
are handled by aldehyde dehydrogenase-2, and when this gene is
also deleted fromFancd2−/−mice, the animals become profoundly
radiosensitive (4, 18); however, this data measuring hematopoi-
etic stem cells in irradiated mice does not answer the question of
whether the lesion is mediated through hematopoietic cells, bone
marrow stromal cells, or both cell phenotypes. The data presented
in cell culture of distinct separated populations of cells (19) sug-
gests that the mechanism is indirect and through the stromal cells
of the microenvironment. The radiosensitivity was documented
by either increased percent ulceration scoring at day 5 after single
fraction irradiation, scoring at day 5 after fractionated irradia-
tion, or in the case of the Fancd2−/− (FVB/N) mouse model
dose response curves were carried out delivering doses ranging
from 24 to 30 Gy. In both model systems and both background
strains, there was uniform radiosensitivity of the Fancd2−/− geno-
type. Table 1 summarizes the results from two recent publications
demonstrating the radiosensitivity of Fancd2−/− mice, including
experiments using single fraction, fractionated irradiation, and
dose response curves. Of interest, the day 2 scoring after irradiation
did not allow a significant variation between mouse genotypes;
however, by day 5, ulceration was well-established and was more
significant in the Fancd2−/− mice (19).
ADMINISTRATION OF THE SMALL MOLECULE REACTIVE OXYGEN
SPECIES SCAVENGER JP4-039 AMELIORATES IRRADIATION-INDUCED
TOXICITY IN VIVO
In both C57BL/6J and FVB/N background mouse strains, admin-
istration of JP4-039/F15 significantly ameliorated irradiation-
induced mucosal ulceration, measured as tongue ulceration
(Table 2). In the C57BL/6J background mouse strain, an additional
control group of F15 emulsion alone showed no difference from
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Table 1 | Radiobiology of Fancd2−/− (Fanconi anemia) mice and bone marrow-derived cell lines.
Mouse strain Total body
irradiation
Longevity of
hematopoiesis
in long-term
marrow cultures
Marrow
mesenchymal
stem cells
Marrow
hematopoietic
progenitor cells
Reference
C57BL/6J (Fancd2−/−) Sensitive Decreased Radiosensitive Radioresistant (2, 11)
C57BL/6J (Fancd2+/−) Intermediate Intermediate Intermediate Intermediate (2, 11)
C57BL/6J (Fancd2+/+) Baseline 22 weeks Baseline Baseline (2, 11)
FVB/N (Fancd2−/−) Sensitive Unknown Radiosensitive Radioresistant (4, 19)
FVB/N (Fand2+/−) Intermediate Unknown Intermediate Intermediate (19)
FVB/N (Fancd2+/+) Baseline Unknown Baseline Baseline (19)
Table 2 | Effect of GS-nitroxide (JP4-039) on radiation biology of Fancd2−/− mice, tissues, and cell lines.
Mouse strain Total body
radiation
Oral cavity Hematopoiesis
in long-term
cultures
Bone marrow
mesenchymal
stem cells
Bone marrow
hematopoietic
progenitor cells
Reference
C57BL/6NHsd (JP4-039) Increased survival Protected Increased Made radioresistant Increased resistance (8, 16, 20)
C57BL/6J Fancd2−/−+ JP4-039 Unknown Protected Unknown Made radioresistant No effect (11)
C57BL/6J Fancd2+/−+ JP4-039 Unknown Unknown Not tested Unknown Made radiosensitive (11)
FVB/N Fancd2+/++ JP4-039 Unknown Protected Not tested Made radioresistant Unknown (19)
FVB/N (Fancd2−/−)+ JP4-039 Unknown Protected Not tested Made radioresistant Unknown (19)
FVB/N Fancd2+/−+ JP4-039 Unknown Unknown Not tested Unknown Unknown (19)
irradiation alone control and documented the effective radia-
tion protective effect of JP4-039. In a four fraction irradiation
experiment delivering 8 Gy daily with JP4-039/F15 administered
immediately before each irradiation fraction, significant radio-
protection was found in Fancd2−/− as well as heterozygote and
Fancd2+/+ mice (C57BL/6J background) (Table 2). The lack
of significant reduction in mucosal ulceration (tongue ulcera-
tion) in mice that had received the liposomal emulsion alone,
F15, documents the radioprotective effect of the small mole-
cule, JP4-039. Figure 1 demonstrates the possible site of action
of JP4-039. JP4-039 is a mitochondrial-targeted nitroxide shown
in the figure in the lower left portion of the cartoon demon-
stration of mitochondria (21). The nitroxide response to the
oxidative stress induced in the mitochondria is both direct by
formation of free radicals inside the mitochondrial intermem-
brane space, but also by diffusion of free radicals across the
mitochondrial membrane. Radical oxygen species (ROS) come
also from nuclear or cytosolic-induced superoxide and hydrogen
peroxide.
Free radicals have been shown to oxidize fatty acids within
the mitochondria, particularly cardiolipin, but also to convert
cytochrome C into a peroxidase, which can further oxidize car-
diolipin (22, 23). Mitochondrial cytochrome C is tightly bound
to cardiolipin and after cardiolipin oxidation is released into
the cytosol. Cytochrome C leaks from the mitochondrial mem-
brane into the cytosol. Cytosolic cytochrome C initiates apoptosis.
Figure 1 demonstrates that targeting of nitroxide to the mitochon-
dria by JP4-039 increases the capacity of the molecule to neutralize
free radicals within the mitochondria, reduce the formation of
oxidized cardiolipin, and reduce the capacity of the mitochondrial
membrane to leak cytochrome C. The mitochondria are clearly
involved in irradiation apoptosis. A summary of the currently
understood mechanism of action of JP4-039 as a normal tissue
radioprotector even in the setting of an in-field tumor is shown
in Figure 2. Figure 2 demonstrates in four panels the proposed
mechanism of action of JP4-039. In the upper left panel, cancer
cells are shown as having fewer mitochondria compared to normal
cells. This is confirmed by recent studies (lower left panel) with five
different tumor cell lines including the mouse head and neck can-
cer cell line TC1, Lewis lung carcinoma (3LL), and human tumor
cell lines TG98, SOC19, and HELA. All are compared to normal
mouse lung with respect to density of mitochondria per weight
of a cell pack. Standardizing to normal lung with a 1.0 number
for density of mitochondria based on Cox-IV as a representative
mitochondrial protein, standardized to GADPH, for four of the
five lines (exception being TG98) shows significant reduction in
mitochondria based on Cox-IV expression. As shown in the upper
right hand panel of Figure 2, reduced mitochondrial gene expres-
sion as measured by RT-PCR is also documented in SC-1 (an oral
squamous cell cancer line) and 3LL mouse tumor lines with respect
to four mitochondrial marker RNA moieties. Only Nrf2 showed
a relative similarity to normal lung in 3LL cells. The lower right
hand panel of Figure 2 is relevant to the Fanconi D2−/− genotype.
In this figure, cells in culture were incubated with JP4-039 labeled
with the BODIPY fluorochrome (17). Mitotracker localizes mito-
chondria, and this is shown in orange in the lower left hand panel.
The BODIPY green color when added alone is shown in the far
right panel lower to be diffusely seen throughout the cytoplasm.
Frontiers in Oncology | Radiation Oncology February 2014 | Volume 4 | Article 24 | 4
Greenberger et al. Radioprotection of radiosensitive individuals
FIGURE 1 |Target of JP4-039 is the mitochondrial mechanism of irradiation-induced apoptosis.
However, when attached to the JP4-039, there is localization of
BODIPY to the mitochondria (upper panels). Combining the
Mitotracker with the BODIPY signal shows mitochondrial local-
ization of BODIPY–JP4-039 to the mitochondria. White arrows in
the upper three panels show mitochondrial localization in a dose
response curve of 1, 2, and 5µM of the BODIPY–JP4-039 going
from left to right in the upper photographs of the lower right
hand panel of Figure 2. By preventing cytochrome C release from
the mitochondria, JP4-039 reduces irradiation-mediated normal
tissue apoptosis (15, 24).
ORAL CAVITY TISSUES ARE RADIOPROTECTED BY JP4-039, AS ARE
BONE MARROW STROMAL CELLS FROM THE FANCD2−/−
BACKGROUND
Radiation survival curves were carried out using clonal cell lines
of bone marrow stromal cells and also hematopoietic progenitor
cells dependent upon IL-3, using cells derived from each of the
three genotypes and each of the two background mouse strains.
A recent publication documents the radiosensitivity of Fancd2−/−
bone marrow stromal cells (11).
THREE DIFFERENT LINES OF EVIDENCE SUGGEST THAT THE
RADIOSENSITIVITY OF THE ORAL CAVITY EPITHELIUM FOLLOWS THAT
OF BONE MARROW STROMAL CELLS AND AS SUCH IS TYPICAL OF
MESENCHYMAL STEM CELLS
Adherent cells from a Fancd2−/− patient were radiosensitive, and
when the Fancd2 gene was re-expressed in these cells, radioresis-
tance was restored in clonogenic survival curve assays, as well as
in assays for DNA strand breaks using the Comet assay and for
depleted antioxidant stores using the Trolox assay (17). In these
studies with human cell lines, JP4-039 was radioprotective when
added to the Fancd2−/− human cells (17). In two different mouse
strains, both FVB/N and C57BL/6J, Fancd2−/− bone marrow stro-
mal cells were radiosensitive compared to those from heterozygote
or Fancd2+/+ wild type genotypes, and the radiosensitive stromal
cells were significantly protected by addition of JP4-039 prior to
irradiation in culture (11).
Hematopoietic cell lines growing in IL-3 culture for several
months,and derived fromFancd2−/− long-term bone marrow cul-
tures, were paradoxically radioresistant. In experiments with both
the C57BL/6J and the FVB/N background mouse strain-derived
long-term bone marrow cultures, Fancd2−/− hematopoietic cells
showed a greater shoulder on the radiation survival curve in
clonogenic survival assay in vitro (11, 19).
Most carcinomas of the head and neck region are squamous cell
in histopathology. Squamous cell tumors and cell lines have fewer
mitochondria due to hypoxia and reduced requirement for oxida-
tive metabolism. Mitochondrial targeting GS-nitroxides protect
cells with increased numbers of mitochondria, which advantages
normal cells (Figure 2). Total bone marrow radiosensitivity in
Fancd2−/− mice might be explained based on the radiation sen-
sitivity of stromal cells, but not hematopoietic cells (11). Bone
marrow stromal cells, which are radiosensitive, are radioprotected
by addition of JP4-039 (11). In the background irradiation control
condition, stromal cells release humoral factors, which are toxic to
hematopoietic cells and may abrogate the association/attachment
of hematopoietic cells with their stroma. Thus, the radiosensitivity
of the hematopoietic stem cell (niche) might overpower intrinsic
radioresistance of hematopoietic cells. Prior studies have demon-
strated that fresh hematopoietic progenitor cells for the colony
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FIGURE 2 | How JP4-039 protects normal tissue.
forming unit granulocyte macrophage (CFU-GM) are radioresis-
tant in the same in vitro clonogenic survival curve assay, indicating
that it is not the IL-3-dependent cell line phenotype, which confers
radioresistance (11).
Fancd2−/− mice are radiosensitive to total body irradiation (2)
and the totipotential reconstituting bone marrow stem cells from
Fancd2−/− mice have been shown to be relatively ineffective for
repopulating total body irradiated recipients (4).
The question of whether systemic administration of JP4-039
can be radioprotective for total body irradiated Fancd2−/− mice
have not yet been investigated. Successful radioprotection by sys-
temic administration of JP4-039, would complement the current
reference studies on head and neck tissue radioprotection by
local administration of JP4-039/F15, and would further strengthen
the argument that the oral cavity tissues are more representa-
tive of bone marrow stromal cells than hematopoietic stem cells
(11, 19).
RECENT STUDIES SHOW THAT MITOCHONDRIAL-TARGETED SMALL
MOLECULE RADIOPROTECTION OF Fancd2−/− (FVB/N) MOUSE ORAL
CAVITY TISSUES DOES NOT ABROGATE EFFECTIVE
RADIO-CONTROLLABILITY OF ORTHOTOPIC TUMORS
In experiments treating orthotopic tumors derived from the TC1
squamous cell carcinoma cell line (derived from C57BL/6J mice),
single fraction or fractionated irradiation of mice with palpable
tumors was successful in Fancd2−/−, heterozygote, and control
Fancd2+/+ mice. In control tumor bearing mice, tumor size
increased similarly in all three mouse strains, and a single fraction
of 28 or 8 Gy times four in a four fraction experiment resulted in
similar tumor radio-controllability and similar tumor size reduc-
tion independent of mouse strain genotype. However, in these
recent experiments, we documented the greater radiosensitivity
of [Fancd2−/− (C57BL/6)] oral cavity tissue and amelioration of
that radiosensitivity in mice receiving JP4-039/F15, even in the
presence of orthotopic tumors.
The radiation survival curve of TC1 tumor cells in vitro was
not altered by JP4-039 administration prior to or after irradia-
tion. Given that JP4-039 has been demonstrated to localize to
the mitochondria (17) and act by stabilization of antioxidant
stores, stabilization of the mitochondrial membrane and preven-
tion of irradiation-induced apoptosis (17), the failure to achieve
these therapeutic goals with tumor cells in vitro and absence
of radiation modification in vivo by administration of JP4-039
in F15 emulsion, suggests that the altered redox status of squa-
mous cell carcinomas in cell lines in vitro or in tumors in vivo,
may facilitate the normal tissue radioprotective action of the
small molecule JP4-039 even in the setting of a DNA repair
defect.
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DISCUSSION
Clinical radiotherapy is complicated in some patients due to their
clinical normal tissue radiosensitivity. Most radiation oncolo-
gists observe that 10% of their patients develop acute radiation
side effects early, and in some cases, with greater intensity and
longer duration, despite administration of palliative drugs, than
other patients. Since most of these clinically radiosensitive patients
do not have a documented genetic defect that could explain
their radiosensitivity (1), most radiation oncologists observe the
radiosensitivity and treat side effects at an earlier time, and con-
tinue the treatments throughout the radiotherapy course. Often in
such patients, a treatment break or reduction in total dose, fraction
size, or treated volume is necessary to minimize toxicity. Radiopro-
tective agents tested in the clinic have been applied uniformly over
populations of patients with no prior knowledge of who might
develop side effects earlier. Such agents include Amifostine, Pal-
ifermin, and GM-CSF (1). They have achieved some success in
local administration, particularly in attempts to palliate a toxic-
ity of head and neck irradiation. In those individuals in whom a
genetic cause of radiosensitivity to clinical radiotherapy is known,
Fanconi anemia patients, additional care is taken before initiation
of irradiation to minimize or prevent side effects. The concern for
extreme toxicity of head and neck irradiation in Fanconi anemia
patients motivates some clinicians to avoid irradiation in the man-
agement of such patients, reserving the therapeutic approach to
surgery alone. Local regional recurrence in such patients, which
may require radiotherapy, is often also restricted, and secondary
surgical procedures are usually undertaken (5).
Fanconi anemia represents a particularly important diagnostic
category for the testing of potential therapeutic benefits of radia-
tion protective agents (6, 7). Susceptibility to DNA double strand
breaks and irradiation-induced cell death as well as the established
background propensity of these patients for bone marrow failure
and secondary malignancy, makes this patient population partic-
ularly vulnerable to radiotherapy toxicity. Regrettably, the high
incidence of epithelial cancers in these patients, both those sur-
viving therapeutic bone marrow transplantation, and those not
transplanted, makes it necessary to design radioprotective strate-
gies for normal tissues in attempts to offer these patients, the same
chance of long-term local control and a cure that is offered to other
patient groups (5, 25–29).
For our studies, we have taken advantage of the robustness of
the animal model system for Fancd2−/− mice (2, 3). The homozy-
gous recombinant deletion genotype is available in two different
background mouse strains, C57BL/6J and FVB/N, making obser-
vations more convincing, if conserved between the two mouse
strains. Recent studies had documented the radiosensitivity of
Fancd2−/− mice, specific tissues and organs from these animals,
and bone marrow stromal cells established from long-term mar-
row culture. Radioprotection of cells in culture, and local tissues of
the head and neck region by administration of an ROS scavenging
small molecule (JP4-039) has been documented in cells and tissues
from both mouse strains. These results provide strong evidence
that an intrinsic DNA repair defect, documented in Fancd2−/−
mice, can be overcome with respect to therapeutic radiation
by administration of a mitochondrial-targeted radioprotectant.
These data further suggest that the initiation of radiation-induced
apoptosis, which occurs in the nucleus with DNA double strand
breaks, may not necessarily be fatal if the downstream effects of this
initiation can be countered. The mitochondria have been shown
to be a critical target for radiation protection given the strong
association of mitochondrial-mediated apoptosis with ionizing
irradiation (12, 17, 20, 30). Previous studies had demonstrated
that initial DNA strand breaks in the nucleus are followed by rapid
activation of DNA repair proteins, first ATM phosphorylation,
activation of the Fanconi pathway, associated molecules includ-
ing BRCA1, BRCA2, RAD51, and RAD52, and at the same time
activation of stress-associated protein kinases, p53 and p21, which
migrate from the nucleus to the mitochondria. At the level of
the mitochondria, within minutes of irradiation of cells in cul-
ture, a cascade of events associated with specific cardiolipin–lipid
peroxidation and disassociation from cytochrome C leads to mito-
chondrial membrane permeability and release of cytochrome C
into the cytoplasm, where the caspase activation system rapidly
triggers apoptosis (15, 22) (Figure 1). Preventing mitochondrial
membrane permeability by targeting the oxidative stress responses
prior to that permeability, and specifically ameliorating lipid per-
oxidation, can be achieved by mitochondrial targeting of ROS
scavengers, namely JP4-039 and other related GS-nitroxides (31–
33). Whether this paradigm would hold in radiosensitive cells,
when the radiosensitivity is based on a known defect in the
DNA repair response, has been unknown. Recent studies with
Fancd2−/− mice in two different background strains, document
the radioprotective capacity of JP4-039 for cells in vitro (11) and
for animal tissues in vivo (19). The available evidence suggests
that patients with intrinsic radiosensitivity, where the phenome-
non is based on a defect in DNA repair, can be protected by the
administration of a mitochondrial-targeted antioxidant.
Studies with Fancd2−/− mice have led to another exciting
observation with respect to the radiobiology of tissue damage.
Fancd2−/− (FVB/N) mice demonstrated suppression of bone mar-
row colony forming progenitor cells at a greater magnitude after
head and neck irradiation, than did heterozygote littermates or
Fancd2+/+ control mice. That the suppression of bone marrow
colony forming cells was also ameliorated by administration of
head and neck localized JP4-039/F15 suggests that the humoral
mediators, through the circulation, which caused the “abscopal”
or “bystander” effect, may be more readily identified in these
interesting Fancd2−/− mice (19, 21, 23, 25–29, 32, 33).
Further studies with Fancd2−/− mice should be helpful in
defining many radiobiologic parameters associated with tissue,
organ, and organ system responses to therapeutic fractionated
irradiation in an intrinsically radiosensitive microenvironment.
Furthermore, radiobiologic studies in tumors bearing Fancd2−/−
and FancG−/− mice may lead to the clinical translation of JP4-
039/F15 as a potential radioprotectant during radiotherapy of
Fanconi anemia patients, or other patients with genetic defects
in DNA repair.
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